pediatric precursor B-cell acute lymphoblastic leukemia
Conditions
Interventions
MR group:On day 19 of induction therapy, blinatumomab was added for 14 days to replace subsequent induction therapy.
HR group:On day 19 of induction therapy, blinatumomab was added for 28 days to replace subsequent induction therapy.
Sponsors
Beijing Children's Hospital, Capital Medical University
Eligibility
Sex/Gender
All
Age
No minimum to 18 Years
Inclusion criteria
Inclusion criteria: 1. Patients diagnosed with CD19-positive BCP-ALL, younger than 18 years old 2. Enrolled in the CCLG-ALL2018 multi-center research protocol and stratified in the intermediate-risk group who have MRD = 1% on the 15th day of induction therapy, and patients in the high-risk group who have been identified after the 15th day of induction therapy. 3. Obtain written informed consent from the parents or legal guardians
Exclusion criteria
Exclusion criteria: 1. Mature B, T-ALL, CD19-negative B-ALL, acute mixed leukemia; 2. ALL secondary to immunodeficiency disease or inherited metabolic disorders; 3. ALL with Down's syndrom; 4. Patients who fail to receive systematic chemotherapy according to the protocol; 5. Patients with clear space-occupying brain parenchyma upon initial diagnosis and those with CNSL who were initially diagnosed and not relieved after treatment
Design outcomes
Primary
| Measure | Time frame |
|---|---|
| minimal residual disease,; | — |
Secondary
| Measure | Time frame |
|---|---|
| remission state of bone marrow;one year event-free survival;overall survival;one year recurrence rate;death rate; | — |
Countries
China
Contacts
Public ContactRuidong Zhang;Tianyou Wang
Beijing Children's Hospital, Capital Medical University
Outcome results
None listed